The tumour suppressor protein p53 is stabilised and activated in response to ionising radiation. This is known to depend on the kinase ATM; recent results suggest ATM acts via the downstream kinase Chk2/hCds1, which stabilises p53 at least in part by direct phosphorylation of residue serine 20. One in three people are touched by cancer at least once in their lifetime. Over half of human tumours are associated with mutations that either directly affect the protein p53 or affect components of pathways that regulate p53. The discovery that 'checkpoint' pathways, which monitor the structural integrity of our chromosomes, stabilise and activate p53 in response to DNA damage indicated how these control systems act to protect organisms from the potentially harmful effects of damaged cells [1] . Upon activation, p53 induces the expression of a variety of gene products, which cause either a prolonged cellcycle arrest in G1, thereby preventing proliferation of damaged cells, or apoptosis, thereby removing damaged cells from our body.
Checkpoint activation requires recognition of DNA damage. Two serine/threonine kinases, ATM and ATR, are thought to act at an early stage in damage sensing. A-T cells, which are derived from cancer-prone ataxiatelangiectasia patients, lack a functional ATM kinase and exhibit chromosomal instability and radiosensitivity. These cells show a significant delay in the up-regulation of p53 in response to ionising radiation, and this defect correlates with a delay in phosphorylation of a serine residue (serine 15) within the amino-terminal transactivation domain of p53 [2] (Figure 1 ). While A-T cells are aberrant in their response to ionising radiation, they show normal UV sensitivity and p53 activation in response to UV-induced DNA damage. The observation that overexpression of a kinase-inactive form of ATR interferes with phosphorylation of p53 residue serine 15 in response to UV light [3] argues that both ATM and ATR upregulate p53 by targeting serine 15.
These observations suggested an attractive model in which phosphorylation of p53 at serine 15 prevented its interaction with MDM2, the protein which targets p53 for proteolysis and prevents its accumulation in undamaged cells. But a link between p53 stabilisation and serine 15 phosphorylation is not consistent with several reports published last year [4] [5] [6] . The biochemical evidence suggests that the mechanism by which serine 15 contributes to p53 activation involves increased binding of phosphorylated p53 to the transcriptional activator CBP/p300, rather than a disassociation of the p53-MDM2 complex [4] .
Serine 20 of p53 lies directly within the MDM2-p53 interaction domain, and the observation that replacement of this residue by alanine abrogates p53 stabilisation in response to both ionising radiation and UV light [5] shifted the focus of research from serine 15 to serine 20. In vitro experiments using peptides bearing non-phosphorylated serine 20 or an alanine substitution provided further support for the importance of this serine residue in the p53-MDM2 interaction [6] . These peptides compete with p53 for MDM2 binding, whereas a similar peptide containing a phosphorylated serine 20 allows the p53-MDM2 association. While ATM is clearly required to activate p53 in response to ionising radiation, both ATM and ATR fail to phosphorylate p53 residue serine 20 in vitro, indicating that, most likely, this residue is targeted by other kinases which act downstream of ATM and ATR.
Two ideal candidates for this job are Chk1 and Chk2, two serine/threonine kinases which become phosphorylated in response to various forms of DNA damage. Chk2 is of particular interest, because it is phosphorylated in an ATM-dependent manner upon treatment with ionising radiation [7] . A new study using Chk2-deficient thymocytes [8] has now shown that Chk2 is indeed required for p53 to be stabilised in response to ionising radiation, and that it is able to phosphorylate p53 at serine 20 in vitro. These new results support a model in which ATM activates Chk2 in response to DNA damage caused by ionising radiation, and that activated Chk2 triggers stabilisation of p53 by phosphorylating residue serine 20 (Figure 2 ). This model is further supported by the recent results of Chehab et al. [9] . This group has demonstrated that Chk2 is able to phosphorylate p53 on serine 20, and that this phosphorylation event triggers dissociation of preformed complexes between p53 and MDM2 under in vitro conditions. Furthermore, ectopic expression of wild-type Chk2 was found to stabilise p53 after DNA damage, whereas expression of a dominant-negative mutant form of Chk2 abrogated both phosphorylation of serine 20 and p53 stabilisation [9] . A close link between Chk2 and p53 is consistent with the recent finding that the Chk2 gene can be mutated in patients suffering from the multicancer disease known as Li-Fraumeni syndrome [10] . This syndrome results normally from the inheritance of a mutant p53 gene, but analysis of an affected family that carries a wild-type p53 gene revealed a germ-line mutation in Chk2.
While Chk2 is required to activate p53 in response to ionising radiation, Hirao et al. [8] found that Chk2 is dispensable for the p53 response in the presence of UVinduced damage. Although there is little definitive experimental evidence, both this observation and the fact that UV damage triggers a normal p53 response in A-T cells support a model in which ATR and Chk1, rather than ATM and Chk2, activate p53 in response to UV-induced damage (Figure 2) . Consistent with such a model, Shieh et al. [11] have found that Chk1 is able to phosphorylate p53 at serine 20 in vitro, and that overexpression of a kinase-defective mutant form of Chk1 leads to reduced levels of p53 protein in co-transfected cells.
There is, however, still much uncertainty about the physiological roles of individual phosphorylation sites in p53. A recent report [12] indicates that it is possible to strip p53 of all of its phosphorylation sites, including serine 15 and serine 20, without significantly affecting either the stabilisation or function of the protein. This result suggests that ATM may promote p53 stabilisation by mediating simultaneous phosphorylation of both partners of the p53-MDM2 complex. Consistent with this suggestion, ATM-dependent phosphorylation of MDM2 has been reported to occur in response to ionising radiation [13] . The complexity of the amino-terminal phosphorylation events may reflect a role in modulating the transcriptional activity of p53, depending on the cellular environment or the type of DNA damage. In this context it will be very interesting to address the physiological role of individual p53 modifications by constructing mice expressing defined mutant forms of p53.
The finding that multiple ATM-dependent phosphorylation events occur within the amino-terminal transactivation domain of p53 raise another question. Why does R316 Current Biology Vol 10 No 8
Figure 1
Four possible ways of activating the tetrameric transcription factor p53 in response to DNA damage. DNA damage is recognised by checkpoint proteins, which target p53 in order to arrest cell-cycle progression in G1 or to promote apoptosis. Dephosphorylation of serine 376 appears to promote binding of a 14-3-3 dimer to p53, which correlates with an increase in its DNA binding affinity. The numbers refer to serine residues phosphorylated in vivo. Domains of p53: TA, transactivation domain; DNA, DNA-binding domain; 4, tetramerisation domain; R, regulatory domain.
ATM target p53 at residue serine 15, while Chk2, which acts downstream of ATM, phosphorylates residue serine 20 in response to ionising radiation? It is not clear, however, whether the same p53 molecule is subjected to both modifications, or whether these modifications reflect events in different cell types. In fact, p53 shows even more ATM-dependent responses to DNA damage. ATM is not only required to stabilise p53 but also to increase its affinity for specific promoter sequences.
The DNA-binding affinity of p53 appears to be regulated by modifications within the carboxy-terminal regulatory domain (Figure 1 ). This region contains one serine residue, serine 376, which is dephosphorylated in response to DNA damage [14] , and several lysine residues, which are acetylated upon DNA damage [15] . Dephosphorylation of serine 376 is ATM-dependent and stimulates the DNA-binding activity of p53 [14] . Acetylation of p53 is up-regulated by phosphorylation of the amino-terminal transactivation domain in vitro, and recent evidence suggests that ATM may stimulate p53 acetylation by phosphorylating residue serine 15 and thereby recruiting the acetyl-transferase CBP/p300 to 53 [4] .
Hirao et al. [8] have reported that Chk2 has a second function, in addition to its crucial role in promoting p53 stabilisation. They found that Chk2 is required to maintain cell-cycle arrest in G2 in a p53-independent manner upon ionising radiation. This aspect of the DNA damage checkpoint resembles very much the checkpoint organisation in unicellular organisms. While p53 is not found in unicellular yeast cells, the organisation of the checkpoint pathways is highly conserved [16] . Upon detection of DNA damage, an ATM-related protein kinase, Rad3 Sp /Mec1 Sc , activates the Chk2-homologue Cds1 Sp /Rad53 Sc in order to arrest the cell cycle (Figure 2 ). During evolution, p53 might have become part of these pre-existing pathways in order to allow the removal of damaged cells.
